Dhampur Bio Organics Ltd (DBOL)
🎯 Key Takeaways
- Dhampur Bio Organics Ltd is in a strategic transition phase, shifting focus from traditional sugar manufacturing to bio-based products, as evidenced by the divestment of its unprofitable Meerganj sugar unit and rebranding toward bio-organics. While core operations remain loss-making, the company is leveraging asset sales and governance reforms to improve financial flexibility and stakeholder confidence.
- Revenue grew 16% QoQ to ₹533 in Q1FY27.
- ⚠️ 1) Core operations continue to generate consistent losses, with no clear path to profitability disclosed, raising concerns about sustainable cash flow
- Market Cap
- ₹824
- P/E Ratio
- 9.7
- P/B Ratio
- 0.80
- ROE
- 8.2%
- ROCE
- 4.8%
- Debt/Equity
- 1.03
- Div Yield
- 1.21%
- Promoter
- 50.8%
📖 The Story
Dhampur Bio Organics Ltd is in a strategic transition phase, shifting focus from traditional sugar manufacturing to bio-based products, as evidenced by the divestment of its unprofitable Meerganj sugar unit and rebranding toward bio-organics. While core operations remain loss-making, the company is leveraging asset sales and governance reforms to improve financial flexibility and stakeholder confidence.
📰 What's Happening
The company has executed a strategic divestment of its Meerganj sugar unit for ₹305 crores, generating a ₹63.89 crore gain and contributing ₹50.54 crores in after-tax profit from discontinued operations, as disclosed in filings dated July 14 and August 13, 2026. This move is part of a broader restructuring effort, supported by the reappointment of Gautam Goel as Chairman and CEO and amendments to governance frameworks at the AGM on July 24, 2026. Additionally, a final dividend of ₹1.50 per share was declared for FY2025-26, signaling confidence in cash flow generation despite ongoing losses in continuing operations.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 558 | 486 | 460 | 533 |
| Operating Profit | -23 | 27 | 67 | -4 |
| OPM % | -4.0% | 5.6% | 14.7% | -0.7% |
| Net Profit | -16 | 17 | 46 | 37 |
| EPS | ₹-2.41 | ₹2.56 | ₹7.01 | ₹5.59 |
Revenue from continuing operations has shown volatility, declining to ₹533 crores in Q1 FY27 from a peak of ₹558 crores in Q3 FY25, while operating losses have widened from ₹-23 crores to ₹-4 crores over the same period, indicating persistent margin pressure. Despite this, profitability improved significantly due to one-time gains from asset sales, with net profit swinging to ₹37 crores in Q1 FY27 from a loss of ₹-16 crores in the prior quarter. The shift reflects a structural transition where financial performance is increasingly influenced by non-core activities rather than operational turnaround.
🔮 Management Outlook & What's Next
Management has not provided forward guidance on the performance of continuing operations or growth prospects for the bio-organics segment in any of the recent filings, including the Q1 FY27 results or AGM resolutions. While the reappointment of Gautam Goel as Chairman and CEO signals leadership continuity, there is no explicit roadmap outlined for achieving profitability in core segments or scaling new business lines.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 66 | 66 | 66 | 66 |
| Reserves | 945 | 905 | 960 | 895 |
| Borrowings | 1,162 | 573 | 1,054 | 562 |
| Total Liabilities | 2,398 | 1,669 | 2,322 | 1,645 |
| Fixed Assets | 1,076 | 1,018 | 1,131 | 1,136 |
| Investments | 0 | 0 | 2 | 2 |
| Total Assets | 2,398 | 1,669 | 2,322 | 1,645 |
The balance sheet shows a significant reduction in net borrowings, declining from ₹1,162 crores in March 2025 to ₹562 crores in March 2026, suggesting active deleveraging, likely accelerated by proceeds from the Meerganj sale. Equity remains stable at ₹66 crores, but reserves have increased from ₹895 to ₹960 crores, reflecting retained earnings from asset sales. This indicates a strategic focus on strengthening the capital structure rather than aggressive reinvestment in operations.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +220 |
| Investing | -42 |
| Financing | -178 |
| Net Cash Flow | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 50.6% | 50.6% | 50.6% | 50.8% |
| FII | 0.3% | 0.5% | 0.5% | 0.3% |
| DII | 0.5% | 0.8% | 0.8% | 0.8% |
| Public | 39.7% | 38.2% | 36.9% | 36.4% |
| # Shareholders | 48,055 | 46,617 | 45,149 | 44,537 |
Promoter holding has remained stable around 50.65–50.78%, indicating no aggressive exit, while institutional interest has modestly increased, with FII ownership rising from 0.35% to 0.54% and DII from 0.45% to 0.82% over the past year. The growing number of shareholders (from 45,149 to 44,537) and consistent retail participation suggest improving market confidence, though foreign institutional exposure remains minimal.
⚖️ Peer Comparison — Sugar
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| BALRAMCHIN | 14,218 | 36.7 | 9.7% | — | 0.69 |
| EIDPARRY | 12,365 | 26.6 | 20.4% | — | 0.32 |
| TRIVENI | 5,274 | 19.2 | 8.4% | — | 0.63 |
| RENUKA | 4,806 | — | -2.9% | — | -3.50 |
| BAJAJHIND | 4,779 | 14.7 | 1.4% | — | 3.74 |
| BANARISUG | 4,125 | 33.9 | 7.3% | — | 0.08 |
| DALMIASUG | 3,341 | 16.4 | 7.0% | — | 0.55 |
| AVADHSUGAR | 1,590 | 24.1 | 6.8% | — | 1.25 |
| GODAVARIB | 1,209 | 7871.7 | 3.8% | — | 0.63 |
| DHAMPURSUG | 1,106 | 15.8 | 6.8% | — | 0.73 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Core operations continue to generate consistent losses, with no clear path to profitability disclosed, raising concerns about sustainable cash flow. 2) Over-reliance on one-time asset sales for profitability, as seen in the ₹50.54 crore gain from discontinued operations, limits long-term earnings resilience. 3) Governance changes, while approved by shareholders, do not guarantee strategic agility or operational improvement in the bio-organics transition.
📋 Recent Filings
- Announcement2026-09-26Dhampur Bio Organics Ltd announced the closure of its insider trading window effective October 1, 2026, until 48 hours after the quarter and half-year…
- 🔴 Announcement2026-09-05CARE Ratings reaffirmed Dhampur Bio Organics' long-term bank facilities at CARE BBB+ with a Positive outlook, reducing the rating from BBB+ Stable to …
- 🟡 Board Meeting2026-08-13Dhampur Bio Organics announced a final dividend of ₹1.50 per share (15% payout) for FY 2025-26, payable to shareholders on record as of July 17, 2026,…
- 🟡 Board Meeting2026-07-26Dhampur Bio Organics Limited held its 6th AGM on July 24, 2026 via video conferencing, passing 11 resolutions including adoption of audited standalone…
- 🟡 Board Meeting2026-07-24Dhampur Bio Organics held its 6th AGM on July 24, 2026, approving FY2025-26 audited standalone and consolidated financial statements, declaring a fina…
- Announcement2026-07-15Dhampur Bio Organics presented Q1 FY27 results showing 4.51% YoY revenue growth to ₹553.88 crores driven by Country Liquor sales, though standalone PA…
- 🟡 Board Meeting2026-07-14The Board of Dhampur Bio Organics Limited approved unaudited consolidated financial results for Q3 FY2026 (ended June 30, 2026) on July 14, 2026, alon…
- 🔴 Financial Results2026-07-14The Board approved unaudited consolidated financial results for Q1 FY27 ending June 30, 2026, showing revenue of **₹918.56 crores**, a loss of **₹13.7…
- share transfer2026-07-10Dhampur Bio Organics Limited received a SEBI-mandated confirmation certificate from Alankit Assignments for the quarter ended June 30, 2026, verifying…
- Announcement2026-07-09Dhampur Bio Organics announced it completed the acquisition of 74% of DBION Private Limited's equity for Rs. 74,000, establishing it as a subsidiary a…
🧠 Analyst's Read
Dhampur Bio Organics is undergoing a structural shift with strategic divestments and governance updates, but the lack of operational momentum in continuing businesses and absence of forward guidance pose significant uncertainty. Investors should monitor future disclosures for clarity on the bio-organics strategy and progress toward operational breakeven.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when DBOL files new disclosures
Track DBOL filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DBOL — FreeFree account · 2 AI queries/day